Pemvidutide, also known as ALT-801, is an experimental peptide from Altimmune that activates the receptors for two hormones, glucagon and GLP-1.1,2 It is not FDA-approved. A Phase 3 trial in the liver disease MASH was recruiting in August 2026, and none of the sources reviewed here reports an approval in any country.3 In IMPACT, a randomized Phase 2 trial of 212 people with MASH and liver fibrosis, pemvidutide met its goal for resolving MASH at 24 weeks but did not meet its goal for improving fibrosis.2
Pemvidutide at a glance
What it is
An investigational glucagon and GLP-1 receptor agonist from Altimmune, also known as ALT-801.1,2
FDA status
Not FDA-approved. Altimmune has registered a Phase 3 trial in MASH on ClinicalTrials.gov.3
Human evidence
One 24-week randomized, double-blind, placebo-controlled Phase 2 trial in 212 people with MASH, with mixed results. Other trials are registered.2,3
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is pemvidutide?
Pemvidutide is an experimental peptide being developed by Altimmune, which ClinicalTrials.gov lists as the sponsor of the IMPACT trial. It is also known by its development code, ALT-801.1
The published IMPACT report describes it as a glucagon and GLP-1 receptor agonist studied in metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease with inflammation.2
How is pemvidutide thought to work?
Pemvidutide is designed to activate the receptors for glucagon and GLP-1, two hormones involved in metabolism, appetite and liver fat.2
The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.2
What do human studies show?
In IMPACT, 212 people with biopsy-confirmed MASH and moderate to advanced liver fibrosis were randomized to pemvidutide or placebo. At 24 weeks, the trial met its goal of MASH resolution without worsening fibrosis.2
It did not meet its second goal, improvement in fibrosis without worsening MASH. Adverse events were reported in 78% and 81% of the pemvidutide groups and 67% of the placebo group.2
A 24-week biopsy result does not show whether people have fewer liver complications over time.2
What the evidence base contains
Controlled human trial IMPACT (NCT05989711): a randomized, double-blind, placebo-controlled Phase 2 trial in 212 people with biopsy-confirmed MASH and stage F2 or F3 fibrosis, with two liver-biopsy goals at 24 weeks.2
Registered trial without results A Phase 3 trial in MASH (NCT07795164) listed as recruiting in its August 31, 2026 registry record.3
Registered trial without results A Phase 2 trial in alcohol use disorder (NCT06987513), listed as completed in its July 31, 2026 record, and a Phase 2 trial in alcohol-associated liver disease (NCT07009860), listed as recruiting.4,5
No. Pemvidutide remains in clinical trials. None of the sources reviewed here reports an approval of pemvidutide in any country.2,3
As of its August 31, 2026 registry record, a Phase 3 trial of pemvidutide in MASH was listed as recruiting on ClinicalTrials.gov.3
Pemvidutide has also been studied in alcohol use disorder, in a Phase 2 trial listed as completed on July 31, 2026, and is being studied in alcohol-associated liver disease.4,5
Timeline
24-week results of the IMPACT Phase 2 trial are published in The Lancet.2
ClinicalTrials.gov updates the IMPACT record, listing the trial as completed.1
ClinicalTrials.gov lists a Phase 2 trial in alcohol use disorder as completed.4
The retained ClinicalTrials.gov record of a Phase 3 trial in MASH lists it as recruiting.3
What is still unknown?
Whether pemvidutide improves liver fibrosis, which IMPACT did not show at 24 weeks.2
What the Phase 3 trial and the alcohol-related trials found or will find: their results are not part of the sources cited here.3,4,5
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Pemvidutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Pemvidutide are the records PeptideScanner has selected and published, not every registration or paper about Pemvidutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
In clinical trials; not FDA-approved. A 24-week randomized Phase 2 trial met its MASH-resolution goal but not its fibrosis goal. A Phase 3 trial in MASH was recruiting in August 2026.↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Two selected reports examine liver-fat changes during an extension study and histologic outcomes in a phase 2 trial. The extension continues an earlier participant cohort; it is not a separate randomized trial.↗↗
What the reviewed sources report
The extension reported liver-fat reductions among selected continuing participants. IMPACT met its MASH-resolution endpoint at 24 weeks but did not demonstrate its fibrosis-improvement endpoint. Longer-term clinical outcomes remain unestablished.↗↗
What remains unresolved?
How do the original trial and selected extension differ in participant retention and outcome analysis?↗↗
What do full reports establish about missing outcomes, sustained histologic changes and longer-term clinical events?↗↗
Two selected reports examine liver-fat changes during an extension study and histologic outcomes in a phase 2 trial. The extension continues an earlier participant cohort; it is not a separate randomized trial.12
Bottom line from this bounded source set
The extension reported liver-fat reductions among selected continuing participants. IMPACT met its MASH-resolution endpoint at 24 weeks but did not demonstrate its fibrosis-improvement endpoint. Longer-term clinical outcomes remain unestablished.12
Reviewed study record
MASLD extension
Design
Double-blind extension of a preceding randomized trial; NCT05292911.1
Population
64 participants from the earlier 94-participant study continued; this is not a new independently randomized cohort.1
Outcomes reported
At 24 weeks, reported relative liver-fat reductions were 56.3%, 75.2% and 76.4% in active groups versus 14.0% with placebo.1
Limitations
Selective extension participation can bias interpretation. MRI liver fat is not the same as histologic fibrosis improvement or patient-important liver outcomes.1
Reviewed study record
IMPACT: biopsy-confirmed MASH
Design
Randomized, double-blind, placebo-controlled phase 2 trial; NCT05989711; two coprimary histology endpoints at week 24.2
Population
212 participants with MASH and stage F2 or F3 fibrosis participated.2
Outcomes reported
The study met the endpoint of MASH resolution without worsening fibrosis, but did not meet the fibrosis-improvement endpoint without worsening MASH. Adverse events were reported in 78% and 81% of active groups versus 67% with placebo.2
Limitations
The abstract does not fully describe handling of missing biopsy outcomes. Longer follow-up was ongoing; a favorable disease-activity endpoint does not establish fibrosis benefit or fewer clinical events.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/j.jhepr.2025.101483. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)02114-2. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
NCT05295875 records 391 participants in a randomized, blinded, placebo-controlled obesity study. Its primary endpoint is relative percentage change in body weight at week 48; metabolic measures and adverse events appear separately. NCT05295875 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
IMPACT asks a liver-disease question
NCT05989711 records 212 participants in a separate placebo-controlled study of non-cirrhotic steatohepatitis. Its primary endpoints include 24-week histological resolution without fibrosis worsening and fibrosis improvement without disease worsening. NCT05989711 ↗
Liver biopsy and imaging endpoints should remain distinct
IMPACT lists MRI-measured liver fat as a secondary outcome alongside the biopsy-based primary endpoints. Less liver fat on imaging is not, by itself, the same finding as improved fibrosis or fewer clinical liver complications. NCT05989711 ↗
Completed records still need a separate results source
Both records are marked completed, but neither retrieved payload contains posted summary results. The last-posted updates are November 29, 2023 for MOMENTUM and May 18, 2026 for IMPACT; publications must be matched and appraised separately. NCT05295875 ↗NCT05989711 ↗
What remains to be checked
Retrieve and appraise MOMENTUM and IMPACT results with their original protocols and analysis plans.
Keep weight, biopsy-based liver outcomes and imaging measures distinct; exclude unrelated drugs sharing the ALT-801 code.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Scoped identity/name search for initial human evidence synthesis; other aliases and preclinical, extension and combination reports require separate eligibility decisions.
16 retrieved · 3 included · 13 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"pemvidutide"[Title/Abstract] OR "alt 801"[Title/Abstract] OR "alt 801"[Title/Abstract]
Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.
Original phase 2 MASLD report PMID39002641 has a publisher correction whose full content remains unavailable; the corrected report is not summarized here.
The 24-week report identifies an extension of the earlier 12-week study; its NCT05292911 extension is grouped with parent NCT05006885. The three included reports still require full-text appraisal and correction reconciliation.
The modeling supplement cites a 2022 first-in-human presentation; that original presentation and its study-family relationship remain unappraised. Excluding this secondary analysis does not discard the citation lead.
Showing 16 of 16 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 41237796 — include: Primary human trial or extension report; the selected abstract establishes the trial identity, while full-text appraisal and registry history remain separate. Study families: NCT05989711.
PubMed 41113119 — include: Primary human trial or extension report; the selected abstract establishes the trial identity, while full-text appraisal and registry history remain separate. The 24-week report follows completers of the original 12-week MASLD study; NCT05292911 is its extension registry. The parent and extension are retained as one study family. Study families: NCT05006885.
PubMed 39002641 — include: Primary human trial or extension report; the selected abstract establishes the trial identity, while full-text appraisal and registry history remain separate. Study families: NCT05006885.
PubMed 42529769 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 41879841 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 41696398 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 41661442 — exclude: Cross-species pharmacokinetic modeling reuses pemvidutide human data from a 2022 first-in-human presentation (supplement Table S1, page 5; reference 11, page 12). It is not an additional primary human-administration report. The presentation remains a citation lead, not a newly appraised trial.Full-text eligibility check · PMC13038672
Read the source full text ↗ · sections Methods: The Dataset of Peptide Drug Pharmacokinetics, Data availability.
PubMed 41352959 — exclude: The author disclosure in the PubMed record explicitly identifies this article as a Comment. It discusses the phase 2b trial rather than reporting an additional primary human-administration study.
Eligibility source ↗ · Conflict-of-interest statement: author identifies this as a Comment · read 2026-09-15.
PubMed 41362110 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 40734920 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 40081498 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 40063921 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 39676791 — exclude: Secondary review, commentary or research overview; not a primary human-administration report for this molecule.
PubMed 35461369 — exclude: Preclinical, genetic or mechanistic study; no primary administration of this molecule to people is reported in the inspected abstract.
PubMed 21994418 — exclude: ALT-801 here refers to an oncology IL-2/T-cell-receptor fusion program or a multi-drug trial roundup, not the pemvidutide GLP-1/glucagon agonist.
PubMed 20383346 — exclude: Multi-drug clinical-trial roundup; does not supply a primary report of pemvidutide administration.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
16 retrieved · 0 included · 0 excluded · 16 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 16 of 16 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT07009860 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01670994 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01326871 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05295875 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06987513 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00496860 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05292911 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01029873 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01478074 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04972396 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04561245 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05134662 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01625260 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07795164 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05006885 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05989711 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Pemvidutide?
In clinical trials; not FDA-approved. A 24-week randomized Phase 2 trial met its MASH-resolution goal but not its fibrosis goal. A Phase 3 trial in MASH was recruiting in August 2026.↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
A status value is unavailable here for 2 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
6
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 6 dated records
We added a plain-language reader guide with cited answers, IMPACT trial results from our human evidence review, and retained ClinicalTrials.gov records for later trials, including a Phase 3 trial in MASH.
PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide.
PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.
Selected records span June 24, 2025 to August 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide.↗